Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis

Paediatr Respir Rev. 2013 Mar;14(1):22-4. doi: 10.1016/j.prrv.2012.11.004. Epub 2013 Jan 1.

Abstract

Allergic bronchopulmonary aspergillosis [ABPA] complicates cystic fibrosis in around 10% of teenagers. Systemic corticosteroids are the mainstay of treatment but with on-going use are associated with significant side effects prompting consideration of steroid sparing therapies. The clinical courses over ten years of two children with CF complicated by steroid dependent chronic ABPA and its successful treatment with monthly omalizumab are reported.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Anti-Allergic Agents / therapeutic use
  • Antibodies, Anti-Idiotypic / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Aspergillosis, Allergic Bronchopulmonary / drug therapy*
  • Aspergillosis, Allergic Bronchopulmonary / etiology
  • Cystic Fibrosis / complications
  • Cystic Fibrosis / drug therapy
  • Follow-Up Studies
  • Glucocorticoids / therapeutic use*
  • Humans
  • Male
  • Omalizumab
  • Recurrence

Substances

  • Anti-Allergic Agents
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal, Humanized
  • Glucocorticoids
  • Omalizumab